Extreme Movers: Claude Sonnet 5.5's picks for 2026-10-20
Claude Sonnet 5.5 picked ALM, MANE, CLF, IRON, AGIO for a 1-day horizon. Average directional return: +0.82%. Directions called correctly: 60%.
| Experiment | Extreme Movers |
|---|---|
| Model | Claude Sonnet 5.5 |
| Prompt version | extreme-movers-v11 |
| Asked | |
| Horizon | 1-day |
| Measured from | 2026-10-20 |
| Measured to | 2026-10-21 |
| Benchmark | SPY |
| Status | Settled |
| Average directional return | +0.82% |
| Directions called correctly | 60% |
| Benchmark return | +0.13% |
The picks
| Rank | Symbol | Direction | Price change | Return in the called direction | Confidence | vs benchmark | Called right |
|---|---|---|---|---|---|---|---|
| 1 | ALM | down | +7.10% | -7.10% | 55% | -7.22% | No |
| 2 | MANE | up | +10.83% | +10.83% | 52% | +10.70% | Yes |
| 3 | CLF | down | +4.80% | -4.80% | 52% | -4.93% | No |
| 4 | IRON | up | +1.69% | +1.69% | 50% | +1.56% | Yes |
| 5 | AGIO | up | +3.47% | +3.47% | 48% | +3.34% | Yes |
The model's market view
Source session Oct 19, 2026: the Nasdaq Composite rose 1.11%, the S&P 500 rose 0.41% and the Dow slipped 0.07% as AI and tech names rebounded from the prior week's selloff. The largest movers were event-driven: healthcare stocks on Phase 3 readouts, Cleveland-Cliffs on an earnings beat, and tungsten miner Almonty on a weak investor day. I lean toward continuation where the catalyst is substantive (positive late-stage clinical data, analyst target cuts after a disappointing event) and toward reversal where the pop has already begun to fade in live trading (CLF). Expected hit rate is only modestly above a coin flip. Average 20-day dollar volume could not be confirmed directly for any pick, so that field is omitted; share-volume data from the quote pages suggests the $20M floor is met for all five.
Why each pick
ALM
Almonty Industries closed Oct 19 at $8.83, down 10.17%, as a tungsten-price slide and a weak investor day weighed on the stock. Stifel cut its target from $25 to $21 and Oppenheimer cut its target from $25 to $19 earlier in the month, and the stock has roughly halved since early September. It was trading lower pre-market at $8.54 (quote around 9:09 AM ET Oct 20, about one hour stale). Catalyst is substantive: sentiment and commodity-price pressure, with no fundamental break in the Sangdong production ramp. Continuation relative to the -10.17% source move means direction down. Market cap of roughly $2.55B and 20-day average volume of about 6.6M shares support the liquidity floors. Risks: oversold (RSI around 23), a $300M buyback authorization, a Strong Buy consensus and short-covering bounces. avg_dollar_volume_20d_usd was not directly confirmed and is omitted.
MANE
Veradermics closed Oct 19 at $122.28, up 12.37%, after its Phase 3 '304' trial of oral VDPHL01 in male pattern hair loss met the co-primary endpoints and all 17 secondary endpoints with a clean safety profile. The catalyst is substantive: clinical data, not speculation. The stock was indicated higher pre-market at $123.45 (about 9:00 AM ET Oct 20, roughly 1 hour stale). Cash is about $820M, which lowers the near-term financing risk. Analyst consensus is Strong Buy with a $163.50 target. Continuation relative to the +12.37% source move means direction up. Market cap is about $5.11B. Risks: sell-the-news fading after the run-up, a possible follow-on offering, and the stock sitting below its early-October highs. avg_dollar_volume_20d_usd was not directly confirmed (20-day average volume about 0.9M shares) and is omitted.
CLF
Cleveland-Cliffs closed Oct 19 at $14.10, up 16.34%, after Q3 adjusted EPS of $0.28 beat expectations and management guided to 2027 adjusted EBITDA above $4B. The pop is partly priced in: the average analyst target is only $12.60 and the consensus rating is Hold. The live quote at 10:16 AM ET Oct 20 was $13.15, down 6.77% from the prior close, so the reversal has already started. I expect further fade as the earnings gap gets sold. Reversal relative to the +16.34% source move means direction down. Market cap is about $7.5B at the live price and the 20-day average volume is about 21.4M shares. Risks: Wells Fargo and Morgan Stanley target raises, a heavily shorted stock (13.8% of shares) and the new highs implied by the guidance, any of which could trigger a squeeze. avg_dollar_volume_20d_usd was not directly confirmed and is omitted.
IRON
Disc Medicine closed Oct 19 at $78.93, up 38.86%, after the Phase 3 APOLLO trial of bitopertin in erythropoietic protoporphyria met all primary and secondary endpoints, with an NDA resubmission planned by year-end 2026. The catalyst is substantive: late-stage clinical data. After the close the company announced a $350M common stock and pre-funded warrant offering, and many analysts raised targets (Cantor to $170, Wells Fargo to $124, Truist to $115). The live quote at 10:17 AM ET Oct 20 was $79.50, near the prior close, so the offering appears to be absorbed. Continuation relative to the +38.86% source move means direction up. Market cap is about $3.05B. Risks: dilution overhang, profit-taking after the largest one-day gain in years, and thin liquidity (about 566K average shares). avg_dollar_volume_20d_usd was not directly confirmed and is omitted.
AGIO
Agios Pharmaceuticals closed Oct 19 at $34.90, up 11.43%, on about 2.0M shares. I could not identify a specific catalyst for the day; the move looks like positioning ahead of the November 1, 2026 FDA decision date for mitapivat in sickle cell disease, which is a substantive upcoming catalyst but is not confirmed as the cause of this move. The stock was flat pre-market at $35.00 (about 9:08 AM ET Oct 20, roughly 1 hour stale). Continuation relative to the +11.43% source move means direction up. Market cap is about $2.08B and the consensus target is $46. Risks: no confirmed catalyst for the jump, sell-the-news ahead of the decision, a prior sickle cell program failure, and a possible fade. avg_dollar_volume_20d_usd was not directly confirmed and is omitted; this pick has the weakest liquidity verification of the five.
Other models on the same run
| Model | Picks | Average directional return | Directions called correctly |
|---|---|---|---|
| GPT-6 | ALM, CLF, IBRX, IRON, MANE | -0.51% | 40% |
| Muse Spark 1.1 | HAS, GM, GE, IREN, KVYO | +2.01% | 60% |
| Perplexity | WDC, DDOG, CLF, AGIO, AMP | +0.14% | 40% |
| Grok 4.5 | CLF, IRON, WDC, AMZN, MOS | +2.30% | 80% |
| Gemini 3 Pro | IRON, CLF, ARQT, DJT, FMC | -0.37% | 40% |
| DeepSeek | CLF, WDC, CTRA, AMP, DDOG | -1.17% | 25% |
Written up on ForecastNest Insights: Extreme Movers: Claude Sonnet 5.5's picks for 2026-10-20.
ForecastNest provides AI-generated market analysis and quantitative research for informational and educational purposes only. Nothing here constitutes financial, investment, legal, or tax advice.